Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06566261 · ClinicalTrials.gov registry record · Phase 1
ABA-101 in Participants With Progressive Multiple Sclerosis
A Phase 1 study of Progressive Multiple Sclerosis, sponsored by Abata Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06566261: Active Phase 1 study of Progressive Multiple Sclerosis, sponsored by Abata Therapeutics.
NCT06566261 is a Phase 1 study of Progressive Multiple Sclerosis that is active but no longer recruiting, run by Abata Therapeutics. The registered enrollment target is 12 participants, below the 23-participant average among 3 other Progressive Multiple Sclerosis trials with a reported enrollment target (48% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06566261, a Phase 1 study of Progressive Multiple Sclerosis, is active but no longer recruiting, sponsored by Abata Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Primary Outcome
Incidence of AEs through Day 29
Conditions Studied
Interventions
- BIOLOGICAL ABA-101
Study Locations (3)
Maryland
- Johns Hopkins University - Baltimore
New Jersey
- Rutgers, Robert Wood Johnson Medical School - New Brunswick
Ohio
- Cleveland Clinic Mellen Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What the registry record for NCT06566261 still lists
NCT06566261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 23-participant average among 3 other Progressive Multiple Sclerosis trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which ABA-101 is the first listed.
NCT06566261 reports a single indexed study location in Maryland, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT06566261 about?
NCT06566261 is a clinical study titled "ABA-101 in Participants With Progressive Multiple Sclerosis". This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
What is the current status of trial NCT06566261?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-09-11. Estimated completion is 2027-02.
What conditions does trial NCT06566261 study?
This clinical trial studies the following conditions: Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT06566261?
The interventions under investigation include: ABA-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06566261?
This trial is sponsored by Abata Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06566261 being conducted?
This trial has 3 study locations across Maryland, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 1
-
Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI